
FDA introduces new pathway for personalised medicines
The US Food and Drug Administration (FDA) has laid out the process and requirements of its novel plausible mechanism pathway for personalised medicine in a New England Journal of Medicine (NEJM) editorial by Commissioner Martin Makary and Deputy Vinay Prasad. The editorial acknowledges that personalised therapies “challenge traditional models of… Read More









